anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The changes in T regulatory cell (Treg) and T helper cell (Th) 17 ratios holds paramount importance in ensuring internal homeostasis and disease progression. Recently, novel subsets of Treg and Th17, namely IL-17-producing Treg and IL-10-producing Th17 have been identified. IL-17-producing Treg and IL-10-producing Th17 are widely considered as the intermediates during Treg/Th17 transformation. These "bi-functional" cells exhibit plasticity and have been demonstrated with important roles in multiple physiological functions and disease processes. Yin and Yang represent opposing aspects of phenomena according to the ancient Chinese philosophy "Yin-Yang" theory. Furthermore, Yin can transform into Yang, and vice versa, under specific conditions. This theory has been widely used to describe the contrasting functions of immune cells and molecules. Therefore, immune-activating populations (Th17, M1 macrophage, etc.) and immune overreaction (inflammation, autoimmunity) can be considered Yang, while immunosuppressive populations (Treg, M2 macrophage, etc.) and immunosuppression (tumor, immunodeficiency) can be considered Yin. However, another important connotation of "Yin-Yang" theory, the conversion between Yin and Yang, has been rarely documented in immune studies. The discovery of IL-17-producing Treg and IL-10-producing Th17 enriches the meaning of "Yin-Yang" theory and further promotes the relationship between ancient "Yin-Yang" theory and modern immunology. Besides, illustrating the functions of IL-17-producing Treg and IL-10-producing Th17 and mechanisms governing their differentiation provides valuable insights into the mechanisms underlying the dynamically changing statement of immune statement in health and diseases.
The participants of the experimental condition will receive the intervention in a talking circle format. They will meet for 10 weekly 50 minute sessions.
Study TMC114-C214 is a randomized (patients are assigned to different treatment groups based on chance), controlled, open-label trial to compare the efficacy (effectiveness), safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in treatment-experienced HIV-1 infected patients. This research study will look at the safety of TMC114 and effectiveness in reducing the amount of HIV(viral load) in the blood. People included in this study will have received either Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) or Protease Inhibitors (PIs) or both. The duration of the study will be approximately 106 weeks, which includes a 4 to 6 week screening period, 96-week treatment period, and 4-week follow-up period. TMC114 300mg are orange tablets where 2 tablets are taken by mouth twice a day with 1 tablet of Ritonavir. Kaletra (LPV/RTV) is either a tablet or capsule taken twice a day. The oral capsule contains 133.3 mg LPV, 33.3 mg RTV and the film-coated tablet is available for oral administration in a strength of 200 mg of lopinavir and 50 mg of ritonavir. Dosing for all medication will occur for 96 weeks and you will be randomly assigned to either TMC114 or Kaletra.
UC is based on a stepped care model for treatment for symptoms of depression. It can include any of the following: active monitoring of depressive symptoms and suicidality, supportive counseling by a healthcare provider, psychosocial support interventions, collaborative care (e.g. facilitation of parental and patient self-management, referral for peer support or other community or school-based behavioral health programs), psychoeducation, complementary and alternative medicine approaches, psychotherapy (e.g. behavioral treatment, interpersonal therapy, cognitive behavioral therapy), pharmacotherapy for mood problems, visit to a primary care provider, behavioral or mental health specialist or therapist, counselor or coach for mood disorder. For purposes of this study, UC will be enhanced by prompting participants to complete a weekly PHQ-8 assessment in a mobile app.
INTRODUCTION: The GOAL Cluster Randomised Controlled Trial (NCT04538157) is now underway, investigating the impact of comprehensive geriatric assessment (CGA) for frail older people with chronic kidney disease (CKD). The primary outcome is the attainment of patient-identified goals at 3 months, assessed using the goal attainment scaling process. The protocol requires a dedicated process evaluation that will occur alongside the main trial, to investigate issues of implementation, mechanisms of impact and contextual factors that may influence intervention success. This process evaluation will offer novel insights into how and why CGA might be beneficial for frail older adults with CKD and provide guidance when considering how to implement this complex intervention into clinical practice.
METHODS AND ANALYSIS: This process evaluation protocol follows guidance from the Medical Research Council and published guidance specific for the evaluation of cluster-randomised trials. A mixed methodological approach will be taken using data collected as part of the main trial and data collected specifically for the process evaluation. Recruitment and process data will include site feasibility surveys, screening logs and site issues registers from all sites, and minutes of meetings with intervention and control sites. Redacted CGA letters will be analysed both descriptively and qualitatively. Approximately 60 semistructured interviews will be analysed with a qualitative approach using a reflexive thematic analysis, with both inductive and deductive approaches underpinned by an interpretivist perspective. Qualitative analyses will be reported according to the Consolidated criteria for Reporting Qualitative research guidelines. The Standards for Quality Improvement Reporting Excellence guidelines will also be followed.
ETHICS AND DISSEMINATION: Ethics approval has been granted through Metro South Human Research Ethics Committee (HREC/2020/QMS/62883). Dissemination will occur through peer-reviewed journals and feedback to trial participants will be facilitated through the central coordinating centre.
TRIAL REGISTRATION NUMBER: NCT04538157.
FIELD: cosmetology. SUBSTANCE: invention relates to the development of cream based on natural components. Curative- prophylactic composition comprises the following components: propolis oily extract, bee wax, cacao oil, fir oil and oily extract from medicinal plants that can be used depending on prescription: for problem skin, in varication and so on. Oily extract comprises the following components: oily extracts prepared from field horse-tail, dioecious nettle, medicinal sage, purple coneflower, purple stonecrop, yellow bedstraw, medicinal hyssop etc. Cream softens skin, protects its against drying, enhances circulation, normalizes mechanisms of tissue metabolism, recovers microflora, prevents early fading and wrinkles appearance. Even after short using cream recovers the natural face color typical for health skin. EFFECT: improved and valuable properties of cream. 4 cl, 4 tbl
An emulsion comprises a perfluorocarbon compound perfluorodecalin and a perfluorocarbon additive and phospholipids in the form of liposomes (vesicles) prepared by homogenization under pressure in an aqueous saline medium. The perfluorocarbon additive is a mixture of perfluorinated products perfluorooctyl bromide and perfluorotripropylamine, and the liposomes (vesicles) contain natural oils as an adjuvant. A method for producing the emulsion comprises producing liposomes (vesicles) by homogenization under a pressure of 60 - 120 atm in an aqueous saline medium followed by hot sterilization, homogenizing said perfluorocarbon compounds under pressure in a liposomal form (vesicles) of phospholipids and performing hot sterilization of the prepared emulsion. The emulsion is intended for improving blood oxygen delivery during the treatment of hypoxic conditions, and for preserving isolated perfused organs and tissues. In accordance with the present invention, the stability of the emulsion is increased while particle structures are preserved, which allows an improvement in the quality of the emulsion and the preservation of biocompatibility with a biological medium (blood, plasma, serum and blood substitutes). The shelf life of the emulsion in an unfrozen form at +4C is at least 23 months with the structure of the emulsion being preserved.
<P>PROBLEM TO BE SOLVED: To provide a health water which is a super mineral water enabling efficient intake of various essential elements and provides an optimum elemental distribution after intake according to the physical condition of each individual, and its preparation process.  <P>SOLUTION: The health water is prepared by mixing an aqueous solution which essentially comprises metal salts and non-metal salts obtained by pulverizing vermiculite derived from weathered black mica or granite and dissolving this into an aqueous sulfuric acid solution, and an aqueous solution obtained by dissolving chitin and chitosan in vinegar or lactic acid. Here, chitin and chitosan are obtained by dissolving pulverized crab shells, etc., in an aqueous sulfuric acid solution and washing away the unwanted matters. The health water enables the body to abundantly ingest ultra-trace elements, which animals and plants often fall short of. After the minimum necessary amounts of trace elements according to the physical condition of each individual are ingested by the body, the remainder binds to chitin and chitosan and is excreted from the body as harmful substances. In addition to their roles as functional food, chitin and chitosan are important for exerting their functions in excreting the excessive micronutrient minerals from the body as harmful substances.  <P>COPYRIGHT: (C)2003,JPO
The invention relates to the field of molecular genetics and biomedicines, in particular to a shRNA for specifically reducing human Aurora-A gene expression and application of the shRNA. The invention provides hairpin interference RNA (ribonucleic acid) for specifically reducing human Aurora-A gene expression, shown by SEQIDNO. 1; an aimed target sequence is the 995th-1015th bit of human Aurora-AmRNA, shown by SEQIDNO. 2; the shRNA can be sheared in vivo or in vitro to form siRNA shown by SEQIDNO. 4 and SEQIDNO. 5; the invention further provides a DNA (deoxyribonucleic acid) oligonucleotide chain for coading the shRNA, shown by SEQIDNO. 3, and a plasmid including the DNA oligonucleotide chain shown by SEQIDNO. 3. According to the invention, after medicines of Aurora-A-shRNA interference carriers transfect human esophageal cancer cells EC9706, an mRNA transcriptional level and a protein expression level of Aurora-A genes in cells are significantly reduced so as to significantly reduce invasiveness of esophageal cancer cells and prompt apoptosis of esophageal cancer cells irradiated and induced by UV (ultra violet), thereby overcoming the defect that the siRNA chemically synthetized in vitro has short acting time, and providing a new way for developing novel antitumor drugs.
Normal saline 5 ml was administered 10 min. after insertion of intravenous cannula IV..
Patients are treated with metformin during the run-in period (3 months) and also after randomization. By randomization sitagliptin tablets will be added.If HbA1c after 6 months of treatment is \> 10 % above the upper limit of normal,then treatment with repaglinide tablets tree times daily at mealtimes will be added.
The present invention provides a prescription and a manufacturing method for nifedipine soft capsule. The prescription comprises nifedipine, a bearer of solid dispersoid, corrective agent etc. The polyethylene glycol 400 defined in the medical industry is taken as the bearer, and the insoluble nifedipine is dispersed into the bearer of the solid dispersion through the solid disperse technology to form the medicament dispersing system with the upper state. The nifedipine soft capsules are produced after the produced content is filled into the soft capsule. The nifedipine soft capsule of the present invention is stable in quality, quick in effect. The bioavailability is evidently improved. After the capsule is pierced and taken under tongue, the antihypertensive effect works in 2 minutes, so the nifedipine soft capsule is in particular suitable for the emergent sufferer with dysphagia symptom or under the particular environment, such as the elder, the carotic patient, the sufferer with elevated blood pressure before operation owing to mental strain.
Hepatitis associated antigen is removed from plasma and plasma fractions by admixing the plasma with ethylene oxide-propylene glycol condensation product at a temperature of from about 0° to 39° centigrade. Under these conditions a precipitate is formed. The concentration of condensation product is adjusted so that all of the hepatitis associated antigen remains either in the precipitate or the liquid phase. Separation of the resultant liquid and solid phases produces a liquid phase which is entirely free of the undesired antigen. The concentration of condensation product which is required to cause complete precipitation of hepatitis associated antigen increases with increasing temperature from a value of about 9 percent, on a weight per volume basis, at about 0° centigrades to a value of about 28 percent at about 39° centigrade. All of the hepatitis associated antigen remains in the liquid phase at condensation product concentrations of less than about 7 percent at about 9° centigrade and about 15 percent at about 39° centigrade. At intermediate concentrations hepatitis associated antigen appears in both phases.
The complications anticipated in the postoperative period after surgical resection of lateral ventricular neoplasms (LVN) are hemorrhage, hydrocephalus. At the N.N. Burdenko Neurosurgery Center, 48 patients with LVN underwent surgical resection. We focused on the correlation between approaches to the ventricular system on one hand and the extent of resection and incidence of complications on the other based on anatomical and perfusion characteristics estimated via preoperative magnetic resonance imaging (MRI) with arterial spin labeling perfusion. By eliminating the surgical approach as a potential risk factor, we were able to demonstrate the correlation between the frequency of postoperative hemorrhage, the Evans index value, patient's gender, tumor blood flow (nTBF) and the location of the mass in the anterior horn of the lateral ventricle. The risk of hemorrhage depends on the patient's gender, presence of hydrocephalus, location of the mass and tumor blood flow values. The risk increases along with increase in Evance index and nTBF values.
A slimming cosmetic or nutraceutical composition (C1) comprises a preparation of sulfated oligosaccharides trapping spermine and/or spermidine, as an active slimming ingredient, optionally in association with another active slimming ingredient, such as caffeine, theophylline, theobromine and/or forskolin. An independent claim is included for a method of a therapeutic treatment to reduce the amount of lipids stored by the adipocytes, including the administration or the topical application of at least one sulfated oligosaccharides or composition (C1). ACTIVITY : Anorectic; Antilipemic. The ex vivo inhibition of lipogenesis was evaluated in suspensions of human adipocytes isolated from 34 year old female during abdominal plasty. The adipocytes suspension was incubated for 2 hours at 37[deg] C with 5% of a solution of sulfated oligosaccharides or in the absence of these solutions (control). At the end of the incubation period, the Non Esterified Fatty Acids (NEFA) which were present in the incubation medium was measured, where the stimulation of lipolysis is indicated by an increase in the concentration of NEFA. The NEFA present in test/control was 200/96 mu M respectively. Thus the solution of sulfated oligosaccharides significantly stimulates lipolysis. MECHANISM OF ACTION : None given.
Intervention in the research groups is professional oral care with tooth brush, "ordinary" fluoridated tooth paste (1100-1450 ppm NaF), and repeated oral care instruction to participants and staff (contact person) , supra gingival depuration if necessary. The group receive treatment each month.
Particles are provided that are not rapidly cleared from the blood stream by the macrophages of the reticuloendothelial system, and that can be modified to achieve variable release rates or to target specific cells or organs. The particles have a biodegradable solid core containing a biologically active material and poly(alkylene glycol) moieties on the surface. The terminal hydroxyl group of the poly(alkylene glycol) can be used to covalently attach onto the surface of the particles biologically active molecules, including antibodies targeted to specific cells or organs, or molecules affecting the charge, lipophilicity or hydrophilicity of the particle. The surface of the particle can also be modified by attaching biodegradable polymers of the same structure as those forming the core of the particles. The typical size of the particles is between 1 nm and 1000 nm, preferably between 1 nm and 100 nm, although microparticles can also be formed as described herein. The particles can include magnetic particles or radiopaque materials, such as air and other gases, for diagnostic imaging, biologically active molecules to be delivered to a site, or compounds for targeting the particles. The particles have a prolonged half-life in the blood compared to particles not containing poly(alkylene glycol) moieties on the surface.
Currently, the abuse of prescription opioid medications is a pervasive problem in the U.S. In addition, co-abuse of opioids and alcohol represents a significant problem from the perspective of increased toxicity and decreased success in treatment. Surprisingly few studies have examined the effects of combined administration of opioids and alcohol in humans, and no clinical studies have examined the reinforcing effects of this combination. The current 8-9-week inpatient study will systematically evaluate gabapentin because it shows promise for treating both opioid and alcohol use disorders (OUD and AUD). The guiding principle is that a medication's effects on positive subjective responses and reinforcing effects are the best laboratory procedures to date in predicting its clinical efficacy. We will examine the ability of gabapentin (0 mg or 1800 mg) to alter opioid-, alcohol-,and combined opioid/alcohol-mediated responses. Participants will meet DSM-5 criteria for moderate-severe OUD and be physically dependent on opioids. In addition, participants will meet DSM-5 criteria for moderate-severe AUD, but they will not be physically dependent on alcohol. All of the participants will be maintained on oral morphine throughout the study and different doses of gabapentin will be evaluated.
Age-at-death estimation is an important issue in forensic medicine and anthropology. Initially, methods relied on morphological criteria, but with the advancement of radiology, new techniques such as morphological studies on multi-slice computed tomography (CT) reconstructions have emerged. Recent studies have shown promising results by investigating the correlation between age and bone mineral density (BMD). However, there is currently a lack of data on post-mortem CTs (PMCT) involving decomposed bodies, and limited information exists regarding changes in Hounsfield Units measurement in a post-mortem context. In light of these gaps, our study aimed to examine the relationship between age at death and pubic and ilium BMD using a sample of forensic bodies. We also aimed to determine whether post-mortem processes, such as putrefaction, could interfere with this correlation. Our retrospective analysis encompassed 637 PMCTs conducted before medicolegal autopsies at Tours University Hospital. Utilizing simple and multiple linear regressions, we investigated the correlation between age and pubic and ilium BMD, as well as the relationship between BMD and the radiologic alteration index (RAI), a scale employed to quantify the degree of putrefaction. Our findings indicate promising outcomes in age-at-death estimation using pubic and/or ilium BMD for bodies exhibiting no or moderate decomposition (RAI < 80), particularly among individuals under 40 years old. However, for highly decomposed corpses (RAI ≥ 80), the presence of gas infiltration significantly influences the BMD of both the ilium and pubis. Consequently, we advocate for the incorporation of the RAI score into the age estimation equation to enhance the accuracy of our results in such cases. Further investigation involving a larger cohort of decomposed bodies could facilitate refinement and validation of our method within this specific population.
Chiari malformations (CM) are often diagnosed in childhood and younger adults, with an incidence of only 0.77% in adult populations. Patients with CM may develop syringomyelia and increased intracranial pressure (ICP) due to cerebrospinal fluid (CSF) obstruction and altered fluid dynamics at the cervicomedullary junction. We describe the case of a 65-year-old female presenting with an angionegative subarachnoid hemorrhage (SAH) with concomitant new diagnosis of CM type I with syringomyelia. After ruling out any aneurysm or vascular malformations, she underwent a suboccipital craniectomy for a Chiari decompression with a C1 laminectomy. There were no complications with the surgery and her symptoms improved. This case report highlights the unusual presentation of a CM.
PURPOSE:To stabilize the vitamin A compound-dissolved aqueous solution by adding at least one of a fat-soluble antioxidizing agent and a water-soluble antioxidizing agent to an aqueous solution containing a vitamin A compound dissolved in the presence of a nonionic surfactant, charging the solution in a container, tightly stoppering the container, and subsequently hermetically sealing the container together with an oxygen-removing agent. CONSTITUTION:At least one kind of a fat-soluble antioxidizing agent (e.g. dibutylhydroxytoluene) and a water-soluble antioxidizing agent (e.g. ascorbic acid) is added to an aqueous solution containing a vitamin A compound dissolved in the presence of a nonionic surfactant. The mixture is charged in a container, tightly stoppered, and hermetically sealed together with an oxygen- removing agent (e.g. iron powder) in a packaging material (plastic container), thereby permitting to stably retain the vitamin A compound-dissolved aqueous solution over a long peric until the package material is opened or also after opened.
Methods and materials for the imaging of cells and tissues containing active proteases such as cathepsin are disclosed. The present materials include activity based probes that bind to an enzyme and are subsequently cleaved. Cleavage results in covalent attachment of a fluorescent signal to a target protease due to removal of a quenching group which, when present on the probe causes altered or no fluorescence. The probes are non-peptidic, small molecule scaffolds linked to a reactive acyloxymethyl ketone group, a fluorophore and a quencher. The probes are cell permeable and may use, for example, a QSY21 (CAS 304014-13-9) quencher and a cyanine dye. The probes form covalent bonds with the active site of cysteine cathepsins, proteases that are upregulated at the tumor boundaries with normal tissue and at sites of inflammation.
Participants will receive GDC-1971 tablet or capsule at assigned dose, orally once daily (QD) on Days 1-21 of each cycle, along with atezolizumab 1200 milligrams (mg) intravenous (IV) infusion once every 3 weeks (Q3W), until unacceptable toxicity or loss of clinical benefit. A subset of participants will participate in evaluations regarding tablet versus (vs) capsule formulations.